Paper28838947
Key signaling pathways in thyroid cancer.
Zaballos MA and 1 other. J Endocrinol, 2017. Cited by 122 papers, by iCite.
Cite this record
ConductScience Library. Key signaling pathways in thyroid cancer. Papers, record 28838947. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28838947
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gene Expression Regulation, Enzymologic | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| MAP Kinase Signaling System | Major topic |
| Phosphatidylinositol 3-Kinases | Major topic |
| Thyroid Neoplasms | Major topic |
| Humans |
Source PubMed
Cited by96
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 122 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42806342 | Synergistic role of molecular imaging and genomics in thyroid cancer management: from diagnosis to personalized treatment. | J Transl Med | 2026 | https://conductscience.org/library/papers/42806342 | PubMed |
| 42724449 | CircFN1 promotes invasion of papillary thyroid carcinoma cells by activating the PI3K/AKT pathway via the miR-29a/TRIB2 axis. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724449 | PubMed |
| 42719379 | Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review. | Cancer Manag Res | 2026 | https://conductscience.org/library/papers/42719379 | PubMed |
| 42559170 | Correction: Multi-gene co-mutations of BRAF with TERT, PIK3CA, or TP53 are powerful predictors of central lymph node metastasis in papillary thyroid carcinoma. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42559170 | PubMed |
| 42483678 | TSH suppression therapy from an individualized perspective: from mechanism to clinical decision-making. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42483678 | PubMed |
| 42207379 | Development of metformin-encapsulated poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42207379 | PubMed |
| 42126497 | Glucose Metabolic Reprogramming in Thyroid Cancer: Underlying Molecular Mechanisms and Links to Progression and Treatment. | Curr Med Sci | 2026 | https://conductscience.org/library/papers/42126497 | PubMed |
| 42039113 | Multifocal papillary thyroid carcinoma with RET p.V804M, EML4-ALK fusion, and BRAF V600E positivity. | JCEM Case Rep | 2026 | https://conductscience.org/library/papers/42039113 | PubMed |
| 41851690 | Identification and validation of hub genes involved in papillary thyroid carcinoma progression. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41851690 | PubMed |
| 41800331 | LncRNA VCAN-AS1 Sponges miR-374c-3p to Promote Proliferation, Invasion, Migration, and EMT in Thyroid Cancer. | Int J Endocrinol | 2026 | https://conductscience.org/library/papers/41800331 | PubMed |
| 41767494 | Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes. | Front Med (Lausanne) | 2026 | https://conductscience.org/library/papers/41767494 | PubMed |
| 41675640 | Multi-gene co-mutations of BRAF with TERT, PIK3CA, or TP53 are powerful predictors of central lymph node metastasis in papillary thyroid carcinoma. | Front Endocrinol (Lausanne) | 2025 | https://conductscience.org/library/papers/41675640 | PubMed |
| 41642503 | Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer. | Curr Oncol Rep | 2026 | https://conductscience.org/library/papers/41642503 | PubMed |
| 41271882 | A Comprehensive multi-network analysis of ceRNAs and transcription factors for papillary thyroid carcinoma diagnosis and prognosis. | Sci Rep | 2025 | https://conductscience.org/library/papers/41271882 | PubMed |
| 41196390 | The role of the primary cilium in thyroid function and dysfunction with implications for thyroid disease. | Histochem Cell Biol | 2025 | https://conductscience.org/library/papers/41196390 | PubMed |
| 41154428 | The Interplay Between lncRNAs-microRNAs Network Dysregulation and Cellular Hallmarks of Thyroid Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41154428 | PubMed |
| 41021127 | Multidimensional transcriptomic and immune profiling of papillary thyroid cancer: bridging molecular networks, disease stage, survival outcomes, and drug discovery. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41021127 | PubMed |
| 40880035 | Systemic Therapy for Advanced Thyroid Cancer-New Personalized Options. | Drugs | 2025 | https://conductscience.org/library/papers/40880035 | PubMed |
| 40819127 | Epigenetic control in thyroid cancer: mechanisms and clinical perspective. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40819127 | PubMed |
| 40806788 | Loss of SPRED3 Causes Primary Hypothyroidism and Alters Thyroidal Expression of Autophagy Regulators LC3, p62, and ATG5 in Mice. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40806788 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28838947
GET https://conductscience.org/api/papers/v1/28838947/cited_by?page=2